Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Date:3/4/2008

XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer

indication

SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). The application is based on a positive opinion CTI received from the EMEA's Scientific Advice Working Party, which agreed to review the application based on the existing results of the phase III clinical trials of XYOTAX, known as the STELLAR trials.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

The application will be formally reviewed for validation by the end of March. Upon validation, the marketing approval review process begins, which generally takes 15 to 18 months.

"This is an important milestone for CTI and demonstrates our commitment to bring XYOTAX to this underserved group of patients. Currently there are no approved treatments for first-line use in PS2 patients with non-small cell lung cancer. Every day counts when treating patients who may have an average life expectancy of only six months, so quality of life an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
11. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market ... Scanner Industry, 2009-2019 is a professional and in-depth ... Crystallography Scanner industry . The report firstly reviews ... its classification, application and manufacturing technology. The report ... X-Ray Crystallography Scanner listing their product specification, capacity, ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... SAN DIEGO, Oct. 2 Pharmatek Laboratories, Inc., a ... industry, announced that it is the first CRO on ... the company,s preclinical and early phase clinical GMP supply ... move our customers, drug candidates into the clinic more ...
... The next major personalized medicine advances will create therapies that ... health care industry to gain access, the inventor of the ... Medical Center,s Personalized Health Care National Conference ... for Systems Biology, said personalized medicine,s first "killer apps" - ...
Cached Medicine Technology:Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast 2Personalized Medicine 'Killer Apps' Will Transform Care Model 2
(Date:8/29/2014)... As reported by GantDaily.com in the article ... , Outbreaks (8/20), the National Institute on Drug Abuse is ... trends by turning to social media. As NIDA currently relies ... also working with the University of Maryland to create a ... which will be funded by the National Institute of Health. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by the ... By Drug Court Grad (8/17), a graduate of the Frederick ... back after his own experience with the program. The graduate, Korey ... also includes a 1 mile walk. He plans to donate the ... well as to those who helped him. Shorb, who graduated in ...
(Date:8/29/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Glass microfiber including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... Dr. Parsa Mohebi M.D. has developed new techniques ... great results in hair transplantation. One of these techniques ... FUE method that harvests facial hair for transplanting to the ... whose hair loss classification is 5 and above achieve reasonable ... alternative for those advanced hair loss patients who may not ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2
... ... Open in Late 2008, BETHESDA, Md., Feb. 19 Fox ... Living, Inc. (NYSE: SRZ ), continues to thrive during one ... already,been reserved to date and construction on the community is at ...
... revolution taking place,and it,s changing the face of cold-beverage ... that,s more sophisticated than traditional,sodas. Many are looking for ... past, finding a healthy and delicious bottled,drink was no ... are,definitely something to get excited about., "The beverage ...
... CHARLOTTE, N.C., Feb. 19 MedCath Corporation,(Nasdaq: ... has entered into,a new strategic relationship with Solaris ... LLC, will participate in a new venture to ... hospitals, JFK,Medical Center and Muhlenberg Regional Medical Center. ...
... 19 With Presidential,candidates campaigning -- and smiling ... Michael Kosdon has had ample opportunity to,judge their ... has,picked a winner., "I would definitely say ... than Hillary Clinton," says Kosdon, who has,transformed hundreds ...
... Inc., the worldwide leader,in handheld X-ray technologies, today ... available. The NOMAD Pro builds upon,the heritage of ... http://www.newscom.com/cgi-bin/prnh/20080219/LATU057 ), "The NOMAD has forever changed ... an operator to safely stay in the room ...
... medication, error prevention outreach and education for HIMSS attendees wearing custom ... ... BRUNO, Calif., Feb. 19 First DataBank, a leading,provider of drug ... to focus public and industry attention on the,prevention of medication errors. ...
Cached Medicine News:Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 2Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 3Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 4Health News:The Search for Healthier Drinks Turns Up Yerba Mate 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Smiling on the Campaign Trail - Cosmetic Dentist Michael Kosdon Rates the Candidates 2Health News:Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 3
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... Agarose, Molecular Biology Grade, is ... of nucleic acids. It can ... fragments from 0.2 to 40 ... Agarose is tested and certified ...
Medicine Products: